Cullinan Therapeutics Inc.
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
CLN-619
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 30 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
Actual Study Start Date : | 2024-09 |
Estimated Primary Completion Date : | 2026-09 |
Estimated Study Completion Date : | 2027-03 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Texas Southwestern Medical Center
dallas, Texas, United States, 75390